Free Trial

CME Group (CME) Stock Forecast & Price Target

CME Group logo
$258.68 -1.16 (-0.45%)
Closing price 03/14/2025 04:00 PM Eastern
Extended Trading
$255.45 -3.23 (-1.25%)
As of 03/14/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CME Group - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
4
Hold
8
Buy
3

Based on 15 Wall Street analysts who have issued ratings for CME Group in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 15 analysts, 4 have given a sell rating, 8 have given a hold rating, and 3 have given a buy rating for CME.

Consensus Price Target

$238.93
-7.63% Downside
According to the 15 analysts' twelve-month price targets for CME Group, the average price target is $238.93. The highest price target for CME is $287.00, while the lowest price target for CME is $180.00. The average price target represents a forecasted downside of -7.63% from the current price of $258.68.
Get the Latest News and Ratings for CME and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CME Group and its competitors.

Sign Up

CME Analyst Ratings Over Time

TypeCurrent Forecast
3/15/24 to 3/15/25
1 Month Ago
2/14/24 to 2/13/25
3 Months Ago
12/16/23 to 12/15/24
1 Year Ago
3/16/23 to 3/15/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
Hold
8 Hold rating(s)
8 Hold rating(s)
7 Hold rating(s)
4 Hold rating(s)
Sell
4 Sell rating(s)
4 Sell rating(s)
4 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$238.93$234.07$226.20$217.30
Forecasted Upside-7.63% Downside-6.41% Downside-4.63% Downside-0.09% Downside
Consensus Rating
Reduce
Reduce
Hold
Hold
Remove Ads

CME Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CME Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

CME Group Stock vs. The Competition

TypeCME GroupFinance CompaniesS&P 500
Consensus Rating Score
1.93
2.52
2.54
Consensus RatingReduceModerate BuyModerate Buy
Predicted Upside-7.63% Downside44.19% Upside19.62% Upside
News Sentiment Rating
Positive News

See Recent CME News
Positive News
Positive News
Remove Ads
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/10/2025Raymond James
4 of 5 stars
Patrick O'Shaughnessy
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$287.00+12.74%
2/19/2025Morgan Stanley
3 of 5 stars
Mike Cyprys
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetEqual Weight ➝ Equal Weight$256.00 ➝ $263.00+6.11%
2/14/2025Keefe, Bruyette & Woods
5 of 5 stars
Kyle Voigt
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetMarket Perform ➝ Market Perform$256.00 ➝ $257.00+3.64%
2/13/2025Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Owen Lau
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$258.00 ➝ $269.00+7.59%
2/13/2025Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Sabadra
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetSector Perform ➝ Sector Perform$235.00 ➝ $269.00+7.59%
2/13/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Kenneth Worthington
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetUnderweight ➝ Underweight$209.00 ➝ $212.00-15.54%
2/13/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Benjamin Budish
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetEqual Weight ➝ Equal Weight$257.00 ➝ $263.00+5.64%
1/7/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$250.00 ➝ $258.00+14.25%
1/6/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Allen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$255.00 ➝ $250.00+7.53%
11/11/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$227.00 ➝ $226.00-0.14%
10/8/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Clinch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$244.00+10.04%
10/3/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSell ➝ Sell$195.00 ➝ $198.00-11.89%
10/3/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetUnderperform ➝ Underperform$177.00 ➝ $180.00-19.49%
9/26/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
W. Katz
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$221.00+1.60%
4/25/2024Rosenblatt Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingSell ➝ Sell$185.00 ➝ $187.00-12.04%
3/6/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$225.00 ➝ $245.00+12.27%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 05:50 AM ET.


Should I Buy CME Group Stock? CME Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, March 11, 2025. Please send any questions or comments about these CME Group pros and cons to contact@marketbeat.com.

CME Group
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in CME Group Inc.:

  • The current stock price of CME Group Inc. is $260.89, which reflects a strong market position and potential for growth.
  • Recent analyst upgrades, such as Raymond James raising the rating to "outperform" with a target price of $287.00, indicate positive sentiment and potential for stock appreciation.
  • The company reported earnings per share of $2.52, exceeding analysts' expectations, showcasing strong financial performance and profitability.
  • CME Group Inc. has a high net margin of 57.52%, which suggests efficient operations and the ability to convert revenue into profit effectively.
  • With a market capitalization of approximately $94 billion, CME Group Inc. is a significant player in the financial services sector, providing stability and investor confidence.

CME Group
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in CME Group Inc. for these reasons:

  • Insider selling has been notable, with a total of 17,076 shares sold recently, which may signal a lack of confidence from those within the company.
  • The stock has experienced fluctuations, with a 52-week high of $263.30 and a low of $190.70, indicating potential volatility that could affect investment stability.
  • Despite positive earnings, the average analyst rating is "Hold," suggesting that many analysts are cautious about the stock's future performance.
  • The company has a relatively high P/E ratio of 27.02, which may indicate that the stock is overvalued compared to its earnings, potentially limiting future price appreciation.
  • With only 0.30% of the stock owned by corporate insiders, there may be a lack of alignment between management and shareholder interests, which can be a red flag for investors.

CME Forecast - Frequently Asked Questions

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for CME Group is $238.93, with a high forecast of $287.00 and a low forecast of $180.00.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CME Group in the last twelve months. There are currently 4 sell ratings, 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "reduce" CME shares.

According to analysts, CME Group's stock has a predicted downside of -7.63% based on their 12-month stock forecasts.

Over the previous 90 days, CME Group's stock had 1 upgrade and 1 downgrade by analysts.

CME Group has been rated by research analysts at Barclays, Citigroup, JPMorgan Chase & Co., Keefe, Bruyette & Woods, Morgan Stanley, Oppenheimer, Piper Sandler, Raymond James, and Royal Bank of Canada in the past 90 days.

Analysts like CME Group less than other "finance" companies. The consensus rating for CME Group is Reduce while the average consensus rating for "finance" companies is Moderate Buy. Learn more on how CME compares to other companies.


This page (NASDAQ:CME) was last updated on 3/15/2025 by MarketBeat.com Staff
From Our Partners